Journal of Glycobiology
Open Access

Influence of O-linked Glycosylation on the Efficacy of Glycoprotein-based Therapeutics

Gora Sheila^{* *}Correspondence: Gora Sheila, Department of Biological Sciences, University of Alberta, Edmonton, Canada, Email:

Author info »

Description

Glycoproteins, proteins that are covalently modified with carbohydrate chains, play an important roles in various biological processes such as cell signaling, immune response, and molecular recognition. The addition of glycans to proteins is essential for their stability, functionality, and trafficking within cells. Among the many types of glycosylation, O-linked glycosylation, where carbohydrates are attached to the hydroxyl group of serine or threonine residues, is particularly significant in determining the functional properties of glycoproteins. In recent years, the growing interest in glycoprotein-based therapeutics, including monoclonal antibodies, enzymes, and cytokines, has highlighted the importance of O-linked glycosylation in modulating their efficacy, safety, and therapeutic potential. This article explains how O-linked glycosylation influences the effectiveness of glycoprotein-based drugs and the implications for their design and production.

O-linked glycosylation in glycoproteins

O-linked glycosylation involves the attachment of carbohydrate chains to the oxygen atom of serine or threonine residues on proteins. Unlike N-linked glycosylation, which occurs at asparagine residues, O-linked glycosylation typically occurs in the Golgi apparatus and involves simpler, shorter carbohydrate chains [1]. These glycans can influence the structural conformation, stability, solubility, and half-life of glycoproteins. In addition, the specific glycan structures attached to a glycoprotein can affect its interaction with other molecules, including receptors, antibodies, and immune cells. O-linked glycosylation is particularly important in regulating the biological activities of many glycoproteins used as therapeutics [2-4]. For instance, mucins, glycoproteins that are highly O-glycosylated, play a key role in immune system modulation, and their glycosylation patterns are closely tied to disease mechanisms. Furthermore, therapeutic proteins like monoclonal antibodies, enzymes used in Enzyme Replacement Therapy (ERT), and recombinant cytokines rely on proper glycosylation for their function [5].

Impact of O-linked glycosylation on therapeutic efficacy
The structure of the glycan attached to a glycoprotein significantly affects its biological activity and therapeutic efficacy. O-linked glycosylation can alter the pharmacokinetics and pharmacodynamics of glycoprotein-based therapeutics, including their distribution, clearance, and immune recognition.

Stability and solubility: O-linked glycosylation can influence the stability of glycoproteins by protecting them from proteolysis and aggregation. For instance, the addition of O-linked glycans can help maintain the structural integrity of therapeutic proteins, thereby enhancing their therapeutic longevity. The presence of specific glycan motifs can also improve the solubility of proteins, reducing aggregation and precipitation, which can compromise the efficacy and safety of therapeutic proteins [6].

Immune response and immunogenicity: One of the most significant factors in the development of glycoprotein-based therapeutics is their potential to trigger an immune response. The glycosylation pattern, including O-linked glycosylation, can influence how the immune system recognizes and responds to therapeutic glycoproteins. Abnormal glycosylation can make therapeutic proteins more immunogenic, leading to the production of antibodies that neutralize the drug or cause allergic reactions. The careful optimization of O-linked glycosylation is therefore essential in reducing the immunogenicity of glycoproteins and improving their therapeutic potential [7].

Half-life and clearance: The presence and structure of O-linked glycans on therapeutic glycoproteins can also impact their half-life in the bloodstream. For example, certain glycosylation patterns may enhance the protein’s ability to evade clearance by the Reticuloendothelial System (RES), thereby increasing its half-life. This can be particularly important in diseases where prolonged exposure to the drug is necessary for optimal therapeutic effects, such as in cancer immunotherapy or chronic inflammatory conditions [8, 9].

Receptor binding and specificity: O-linked glycosylation can modulate the binding affinity and specificity of glycoproteins to their target receptors. For example, O-glycosylation of glycoproteins can influence how they interact with cell surface receptors, such as those involved in immune modulation or tumor targeting. This is crucial for the efficacy of glycoprotein-based therapeutics, as enhanced or specific receptor binding can increase therapeutic efficacy while minimizing off-target effects [10].

Conclusion

O-linked glycosylation plays a critical role in the function and efficacy of glycoprotein-based therapeutics. Its impact on the stability, solubility, immunogenicity, half-life, and receptor binding of therapeutic proteins underscores the need for precise control of glycosylation patterns in drug development. As biotechnological advancements continue to refine our understanding and manipulation of O-linked glycosylation, the ability to design more effective and safer glycoprotein-based therapeutics will significantly improve, offering treatment for patients with a wide range of diseases.

References

1. Solá RJ, Griebenow K. Glycosylation of therapeutic proteins: An effective strategy to optimize efficacy. BioDrugs. 2010;24(1):9-21.

   [Crossref] [Google Scholar] [PubMed]

2. Zhang P, Woen S, Wang T, Liau B, Zhao S, Chen C, et al. Challenges of glycosylation analysis and control: An integrated approach to producing optimal and consistent therapeutic drugs. Drug Discov Today. 2016;21(5):740-765.

   [Crossref] [Google Scholar] [PubMed]

3. Hang HC, Bertozzi CR. The chemistry and biology of mucin-type O-linked glycosylation. Bioorg Med Chem. 2005;13(17):5021-5034.

   [Crossref] [Google Scholar] [PubMed]

4. Naseri R, Navabi SJ, Samimi Z, Mishra AP, Nigam M, Chandra H, et al. Targeting Glycoproteins as a therapeutic strategy for diabetes mellitus and its complications. Daru. 2020;28:333-358.

   [Crossref] [Google Scholar] [PubMed]

5. Almeida A, Kolarich D. The promise of protein glycosylation for personalised medicine. Biochim Biophys Acta. 2016;1860(8):1583-1595.

   [Crossref] [Google Scholar] [PubMed]

6. DiPaola M, Li J, Stephens E. Development of biosimilars: Analysis of etanercept glycosylation as a case study. J Bioanal Biomed. 2013;5(5):180-186.

   [Crossref] [Google Scholar]

7. Reis CE, Milessi TS, Ramos MD, Singh AK, Mohanakrishna G, Aminabhavi TM, et al. Lignocellulosic biomass-based glycoconjugates for diverse biotechnological applications. Biotechnol Adv. 2023;68:108209.

   [Crossref] [Google Scholar] [PubMed]

8. Schoen K, Lepenies B, Goyette-Desjardins G. Impact of protein glycosylation on the design of viral vaccines. Adv Biochem Eng Biotechnol. 2021:319-354.

   [Crossref] [Google Scholar] [PubMed]

9. Thomas D, Rathinavel AK, Radhakrishnan P. Altered glycosylation in cancer: A promising target for biomarkers and therapeutics. Biochim Biophys Acta Rev Cancer. 2021;1875(1):188464.

   [Crossref] [Google Scholar] [PubMed]

10. Wang Y, Wang X, Ma G, Xie L, Liu D, Wang Y, et al. Sustainable production of a polysaccharide-based glycoprotein by simultaneous conversion of glucose and glycerol in engineered Escherichia coli. Green Chemistry. 2023;25(12):4818-32.

    [Crossref] [Google Scholar]